1.93
-0.05(-2.53%)
Currency In USD
| Previous Close | 1.98 |
| Open | 1.98 |
| Day High | 1.99 |
| Day Low | 1.91 |
| 52-Week High | 13.07 |
| 52-Week Low | 1.29 |
| Volume | 527,201 |
| Average Volume | 1.18M |
| Market Cap | 114.85M |
| PE | -0.64 |
| EPS | -3 |
| Moving Average 50 Days | 1.79 |
| Moving Average 200 Days | 2.8 |
| Change | -0.05 |
If you invested $1000 in Biomea Fusion, Inc. (BMEA) since IPO date, it would be worth $103.76 as of September 13, 2025 at a share price of $1.93. Whereas If you bought $1000 worth of Biomea Fusion, Inc. (BMEA) shares 3 years ago, it would be worth $145.11 as of September 13, 2025 at a share price of $1.93.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Biomea Fusion Appoints Julianne Averill to its Board of Directors
GlobeNewswire Inc.
Jul 24, 2025 11:00 AM GMT
SAN CARLOS, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced the appointment of Julianne Averill to i
Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)
GlobeNewswire Inc.
Jun 23, 2025 11:00 AM GMT
In a rodent model of type 2 diabetes (T2D), icovamenib in combination with low-dose semaglutide promoted enhanced glycemic control and body weight reduction with complete preservation of lean mass, outperforming the group given semaglutide aloneIcova
Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates
GlobeNewswire Inc.
Jun 18, 2025 11:00 AM GMT
Dose-dependent, marked reductions in food intake and significant weight loss observed in obese cynomolgus monkeys BMF-650 compared favorably to published data of a leading GLP-1 RA candidate IND filing on track for the second half of 2025; with Phase